CLVS Clovis Oncology, Inc.

57.86
+1  (2%)
Previous Close 56.92
Open 57.31
Price To book 0.00
Market Cap 2.58B
Shares 44,626,000
Volume 1,241,759
Short Ratio 3.82
Av. Daily Volume 1,945,580

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Pivotal trial initiated late 2013. Enrollment completed 2Q 2016. Data due mid-2017.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line